Clinical trials: Recurrent Head and Neck Carcinoma
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Thyroid Cancer, Surgery
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis.According to the 2015 American thyroid association (ATA) guidelines, no gross extrathyroidal extension and the number of pathological…
- Conditions
- Thyroid Cancer, Surgery, Recurrence
- Trial name
- NCT06087068
- Testing
- Thyroxine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Cancer
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00079079
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Trial name
- NCT01474642
- Testing
- Capecitabine/Cisplatin(XP), Capecitabine/Paditaxel(XG)
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Samsung Medical Center
Metastatic Head-and-neck Squamous-cell Carcinoma
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
The primary hypothesis is that the objective response rate (ORR) with nab-paclitaxel and nivolumab will be significantly higher than the historical control (ORR 30%).
- Trial name
- NCT04831320
- Testing
- nab-paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
SCCHN
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head…
- Trial name
- NCT03771820
- Testing
- NC-6004, Pembrolizumab
- Where
- 24 sites in Croatia, Czechia and 6 more
- Volunteers
- 136 people
- Sponsor
- NanoCarrier Co., Ltd.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Lung Cancer, Vulvar Cancer
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and…
- Conditions
- Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer
- Trial name
- PEVOsq (NCT04357873)
- Testing
- pembrolizumab; vorinostat
- Where
- 14 sites in France
- Volunteers
- 112 people
- Sponsor
- UNICANCER
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
This phase I trial is studying the side effects and best dose of sunitinib when given together with cetuximab and radiation therapy in treating patients with locally advanced or recurrent squamous cell carcinoma of the head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00906360
- Testing
- sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of Head and Neck
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck
AIO-KHT-0117 (OPTIM) is a phase II, open-label randomized, multicenter study of nivolumab and ipilimumab on the optimization of immunotherapy in squamous carcinoma of the head and neck after prior platinum-based therapy.
- Trial name
- OPTIM (NCT03620123)
- Testing
- Nivolumab and Ipilimumab, Docetaxel
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- AIO-Studien-gGmbH
Head and Neck Cancer
Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma
This trial will evaluate safety and efficacy of the combination of anti-PD1, NKTR-214, and palliative radiation therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Trial name
- NCT04936841
- Testing
- NKTR-214, anti-PD-1 therapy, Palliative Radiation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison
Nasopharyngeal Carcinoma
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC
- Trial name
- NCT05654077
- Testing
- CAR-T Cell Injection, Fludarabine, cyclophosphamide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05182866
- Testing
- ASP-1929 Photoimmunotherapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rakuten Medical, Inc.
Carcinoma, Squamous Cell
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a…
- Trial name
- NCT00041626
- Testing
- INGN 201
- Where
- 8 sites in United States
- Sponsor
- Introgen Therapeutics
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery.
- Conditions
- Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03468218
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Nasopharyngeal Carcinoma
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy
To evaluate the sensitivity and specificity of the combination of EBV and methylation marker genes in body fluids of both plasma and nasopharyngeal brush together for screening of early salvageable local residual and recurrent…
- Trial name
- NCT03379610
- Testing
- Nasopharngeal brush
- Volunteers
- 426 people
- Sponsor
- The University of Hong Kong
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Bevacizumab may reduce CNS side effects caused by radiation therapy. This randomized phase II trial is studying how well bevacizumab works in reducing CNS side effects in patients who have undergone radiation therapy to the brain…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT00492089
- Testing
- bevacizumab, magnetic resonance imaging, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT05523323
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 28 sites in China
- Volunteers
- 112 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Squamous Cell Cancer (SCC), Recurrent Laryngeal Nerve Palsy
CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal Cancer
The goal of this observational study is to develop a predictive model for left recurrent laryngeal nerve (RLN) lymph node metastasis using deep learning algorithms.
- Conditions
- Esophageal Squamous Cell Cancer (SCC), Recurrent Laryngeal Nerve Palsy, Deep Learning, Postoperative Complication
- Trial name
- NCT07074535
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.